Casdin Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Casdin Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.8M	Hold	75,000	–	–	1.88%	13
2025 Q4	$29.8M	Buy	75,000 +20,000	+36%	+$8.85M	1.85%	13
2025 Q3	$25.1M	Sell	55,000 -26,500	-33%	-$10.8M	2.09%	10
2025 Q2	$26.6M	Sell	81,500 -38,500	-32%	-$10.7M	2.42%	9
2025 Q1	$32.4M	Sell	120,000 -20,000	-14%	-$5.14M	2.65%	8
2024 Q4	$32.9M	Sell	140,000 -30,000	-18%	-$7.89M	2.19%	11
2024 Q3	$46.8M	Hold	170,000	–	–	3.12%	9
2024 Q2	$41.3M	Sell	170,000 -188,000	-53%	-$29.7M	3.15%	10
2024 Q1	$53.5M	Buy	358,000 +163,000	+84%	+$27.2M	3.98%	6
2023 Q4	$37.3M	Sell	195,000 -5,000	-3%	-$852K	3.66%	9
2023 Q3	$35.4M	Sell	200,000 -80,000	-29%	-$15.3M	3.92%	9
2023 Q2	$53.2M	Buy	280,000 +10,000	+4%	+$1.98M	4.65%	5
2023 Q1	$54.1M	Sell	270,000 -95,000	-26%	-$20M	4.46%	6
2022 Q4	$86.7M	Sell	365,000 -283,000	-44%	-$60.4M	6.72%	4
2022 Q3	$130M	Sell	648,000 -157,000	-20%	-$29.9M	8.52%	4
2022 Q2	$117M	Sell	805,000 -195,000	-20%	-$27.7M	9.93%	2
2022 Q1	$163M	Hold	1,000,000	–	–	7.32%	2
2021 Q4	$170M	Hold	1,000,000	–	–	4.78%	5
2021 Q3	$189M	Hold	1,000,000	–	–	4.7%	6
2021 Q2	$170M	Buy	1,000,000 +120,000	+14%	+$17.6M	4.3%	7
2021 Q1	$124M	Buy	880,000 +100,000	+13%	+$15M	3.7%	7
2020 Q4	$101M	Buy	780,000 +160,000	+26%	+$21.4M	3%	11
2020 Q3	$90.3M	Buy	620,000 +70,000	+13%	+$9.95M	4.04%	7
2020 Q2	$81.5M	Sell	550,000 -35,000	-6%	-$4.72M	4.82%	6
2020 Q1	$63.7M	Buy	585,000 +70,000	+14%	+$8.08M	6.76%	3
2019 Q4	$59.3M	Sell	515,000 -85,000	-14%	-$8.47M	5.45%	6
2019 Q3	$48.3M	Sell	600,000 -50,000	-8%	-$3.96M	4.99%	9
2019 Q2	$47.2M	Buy	650,000 +205,000	+46%	+$15.7M	4.41%	10
2019 Q1	$41.6M	Buy	445,000 +90,000	+25%	+$7.53M	4.57%	10
2018 Q4	$25.9M	Buy	355,000 +85,000	+31%	+$6.54M	4.43%	11
2018 Q3	$23.6M	Hold	270,000	–	–	2.87%	17
2018 Q2	$26.6M	Buy	270,000 +20,000	+8%	+$1.98M	3.72%	12
2018 Q1	$29.8M	Buy	250,000 +50,000	+25%	+$6.45M	5.24%	7
2017 Q4	$25.4M	Hold	200,000	–	–	6.19%	6
2017 Q3	$23.5M	Buy	200,000 +95,000	+90%	+$8.11M	6.64%	3
2017 Q2	$8.38M	Buy	105,000 +50,000	+91%	+$3.2M	3.1%	12
2017 Q1	$2.82M	Sell	55,000 -30,000	-35%	-$1.39M	1.66%	24
2016 Q4	$3.18M	Buy	85,000 +46,000	+118%	+$1.93M	2.63%	16
2016 Q3	$2.64M	Sell	39,000 -33,500	-46%	-$2.36M	2.14%	16
2016 Q2	$4.02M	Sell	72,500 -17,500	-19%	-$1.1M	4%	10
2016 Q1	$5.65M	Buy	90,000 +30,000	+50%	+$1.99M	6.48%	7
2015 Q4	$5.65M	Buy	+60,000	New	+$5.56M	4.99%	11

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital's ALNY Position: Q1 2026 in Review

Casdin Capital held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 75,000 shares worth $24.8M. The position accounts for 1.88% of the portfolio, ranked #13.

Casdin Capital first reported a position in ALNY in Q4 2015 and has held it in 42 quarters since. The position peaked at $189M in Q3 2021. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Casdin Capital held 75,000 shares of Alnylam Pharmaceuticals worth $24.8M as of Q1 2026.
Casdin Capital left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up 1.88% of Casdin Capital's portfolio in Q1 2026, its #13 holding.
Casdin Capital first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
Casdin Capital's Alnylam Pharmaceuticals position peaked at $189M in Q3 2021.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.